These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25744294)

  • 1. The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells.
    Fang WB; Yao M; Jokar I; Alhakamy N; Berkland C; Chen J; Brantley-Sieders D; Cheng N
    Breast Cancer Res Treat; 2015 Apr; 150(2):309-20. PubMed ID: 25744294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression.
    Chen F; Li A; Gao S; Hollern D; Williams M; Liu F; VanSickle EA; Andrechek E; Zhang C; Yang C; Luo R; Xiao H
    Cell Death Dis; 2014 May; 5(5):e1242. PubMed ID: 24853420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.
    Fang WB; Yao M; Brummer G; Acevedo D; Alhakamy N; Berkland C; Cheng N
    Oncotarget; 2016 Aug; 7(31):49349-49367. PubMed ID: 27283985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.
    Katanov C; Lerrer S; Liubomirski Y; Leider-Trejo L; Meshel T; Bar J; Feniger-Barish R; Kamer I; Soria-Artzi G; Kahani H; Banerjee D; Ben-Baruch A
    Stem Cell Res Ther; 2015 May; 6(1):87. PubMed ID: 25928089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCL2-driven inflammation increases mammary gland stromal density and cancer susceptibility in a transgenic mouse model.
    Sun X; Glynn DJ; Hodson LJ; Huo C; Britt K; Thompson EW; Woolford L; Evdokiou A; Pollard JW; Robertson SA; Ingman WV
    Breast Cancer Res; 2017 Jan; 19(1):4. PubMed ID: 28077158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments.
    Brummer G; Fang W; Smart C; Zinda B; Alissa N; Berkland C; Miller D; Cheng N
    Oncogene; 2020 Mar; 39(11):2275-2289. PubMed ID: 31827233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.
    Caruso JA; Karakas C; Zhang J; Yi M; Albarracin C; Sahin A; Bondy M; Liu J; Hunt KK; Keyomarsi K
    Breast Cancer Res; 2014; 16(6):3417. PubMed ID: 25551582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo.
    Lavender N; Yang J; Chen SC; Sai J; Johnson CA; Owens P; Ayers GD; Richmond A
    BMC Cancer; 2017 Jan; 17(1):88. PubMed ID: 28143493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.
    Barham W; Chen L; Tikhomirov O; Onishko H; Gleaves L; Stricker TP; Blackwell TS; Yull FE
    BMC Cancer; 2015 Sep; 15():647. PubMed ID: 26424146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.
    Nam JS; Kang MJ; Suchar AM; Shimamura T; Kohn EA; Michalowska AM; Jordan VC; Hirohashi S; Wakefield LM
    Cancer Res; 2006 Jul; 66(14):7176-84. PubMed ID: 16849564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of carbonic anhydrase IX protein expression in molecular subtyping of breast cancers].
    Li MP; Ren LF; Cai HG; Yang HY; Lu B; Zhang P; Bao L
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):182-5. PubMed ID: 23769438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome.
    Hsing CH; Cheng HC; Hsu YH; Chan CH; Yeh CH; Li CF; Chang MS
    Clin Cancer Res; 2012 Feb; 18(3):713-25. PubMed ID: 22186257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of beclin-1 in the microenvironment of invasive ductal carcinoma of the breast: correlation with prognosis and the cancer-stromal interaction.
    Morikawa A; Takeuchi T; Kito Y; Saigo C; Sakuratani T; Futamura M; Yoshida K
    PLoS One; 2015; 10(5):e0125762. PubMed ID: 25955408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mouse model for luminal epithelial like ER positive subtype of human breast cancer.
    Kumar MJ; Ponvijay KS; Nandhini R; Nagarajan RS; Jose J; Srinivas G; Nagarajan P; Venkatesan R; Kumar K; Singh S
    BMC Cancer; 2007 Sep; 7():180. PubMed ID: 17880731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.